What the studies show
REDEFINE 2: 13.7% loss against 3.4% on placebo — the usual smaller effect in people with diabetes. Nearly three-quarters reached an HbA1c of 6.5% or below.
“The estimated mean change in body weight from baseline to week 68 was -13.7% in the cagrilintide-semaglutide group and -3.4% in the placebo group (estimated difference, -10.4 percentage points; 95% confidence interval, -11.2 to -9.5; P<0.001).”
Several well-run randomised trials in people, pointing the same way. You can plan around this. It still says nothing about whether the effect is worth the side effects for you.
- 1Davies MJ, et al. Cagrilintide-semaglutide in adults with overweight or obesity and type 2 diabetes (REDEFINE 2).N Engl J Med, 20251,206 randomised, 68 weeks. NCT05394519.
In context
CagriSema is a once-weekly co-injection of cagrilintide, an amylin analogue, with semaglutide 2.4 mg. In REDEFINE 1, a 3,417-person phase 3 trial published in 2025, it produced 20.4% average weight loss at 68 weeks against 3.0% on placebo; in people with type 2 diabetes the figure was 13.7%. Both trials are peer-reviewed. It is not yet approved anywhere, and anything sold under the name is not the trial product.
CagriSema is investigational (filed). Legal status differs by country — see the regulation section or the jurisdiction pages.
Questions
Is CagriSema proven to help with body weight?
What studies are behind the grade?
Is CagriSema approved for this?
Other outcomes for CagriSema
- ABody weight (obesity without diabetes)1 phase 3 RCT (n=3,417, 68 wk)
- ABlood glucose (HbA1c) in type 2 diabetes1 phase 3 RCT (n=1,206)
- BBody weight (vs tirzepatide 5 mg, type 2 diabetes)1 phase 3 RCT topline (REIMAGINE 5, 60 wk)
- AGI side effectsadverseBoth phase 3 RCTs
Written and maintained by LYO Research — how pages are written and checked. Reviewed 7 October 2026. Grades count human evidence only; see how LYO grades. Not medical advice. Correct this page →